Network meta-analysis evaluates prolyl hydroxylase inhibitors for anemia management in chronic kidney disease, indicating varying effectiveness and safety profiles.
Key Points
The research aims to evaluate the effectiveness and safety of prolyl hydroxylase inhibitors compared to erythropoiesis-stimulating agents for treating anemia in chronic kidney disease.
Conducted a Bayesian network meta-analysis of 46 randomized controlled trials
Included data from 32,305 patients with chronic kidney disease
Focus on primary outcome of hemoglobin change and secondary outcomes of iron metabolism and adverse events analysis
Roxadustat showed the largest hemoglobin increase in both non-dialysis and dialysis patients
ESA demonstrated superior transferrin saturation in non-dialysis chronic kidney disease patients
Adverse events were lowest for ESA in non-dialysis CKD, while roxadustat had a higher incidence
Roxadustat improved serum iron levels significantly in dialysis chronic kidney disease